These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 19623477)
41. A review on remediation of cyanide containing industrial wastes using biological systems with special reference to enzymatic degradation. Sharma M; Akhter Y; Chatterjee S World J Microbiol Biotechnol; 2019 Apr; 35(5):70. PubMed ID: 31011828 [TBL] [Abstract][Full Text] [Related]
42. Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery: building chiral technology toolboxes. McConnell O; Bach A; Balibar C; Byrne N; Cai Y; Carter G; Chlenov M; Di L; Fan K; Goljer I; He Y; Herold D; Kagan M; Kerns E; Koehn F; Kraml C; Marathias V; Marquez B; McDonald L; Nogle L; Petucci C; Schlingmann G; Tawa G; Tischler M; Williamson RT; Sutherland A; Watts W; Young M; Zhang MY; Zhang Y; Zhou D; Ho D Chirality; 2007 Sep; 19(9):658-82. PubMed ID: 17390370 [TBL] [Abstract][Full Text] [Related]
44. Scalable enantioselective processes for chiral pharmaceutical intermediates. Iida T; Mase T Curr Opin Drug Discov Devel; 2002 Nov; 5(6):834-51. PubMed ID: 12478715 [TBL] [Abstract][Full Text] [Related]
45. Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real. de Gonzalo G; Alcántara AR; Domínguez de María P; Sánchez-Montero JM Expert Opin Drug Discov; 2022 Oct; 17(10):1159-1171. PubMed ID: 36045591 [TBL] [Abstract][Full Text] [Related]
47. Advances in biocatalytic synthesis of pharmaceutical intermediates. Panke S; Wubbolts M Curr Opin Chem Biol; 2005 Apr; 9(2):188-94. PubMed ID: 15811804 [TBL] [Abstract][Full Text] [Related]
48. Drug discovery and natural products: end of an era or an endless frontier? Li JW; Vederas JC Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993 [TBL] [Abstract][Full Text] [Related]
49. The nitrilase family of CN hydrolysing enzymes - a comparative study. O'Reilly C; Turner PD J Appl Microbiol; 2003; 95(6):1161-74. PubMed ID: 14632988 [TBL] [Abstract][Full Text] [Related]
50. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds. Calcaterra A; D'Acquarica I J Pharm Biomed Anal; 2018 Jan; 147():323-340. PubMed ID: 28942107 [TBL] [Abstract][Full Text] [Related]
51. Potential and capabilities of hydroxynitrile lyases as biocatalysts in the chemical industry. Purkarthofer T; Skranc W; Schuster C; Griengl H Appl Microbiol Biotechnol; 2007 Aug; 76(2):309-20. PubMed ID: 17607575 [TBL] [Abstract][Full Text] [Related]
53. Epoxide hydrolases and their synthetic applications. Orru RV; Archelas A; Furstoss R; Faber K Adv Biochem Eng Biotechnol; 1999; 63():145-67. PubMed ID: 9933984 [TBL] [Abstract][Full Text] [Related]
54. Biocatalysis for the synthesis of pharmaceuticals and pharmaceutical intermediates. Sun H; Zhang H; Ang EL; Zhao H Bioorg Med Chem; 2018 Apr; 26(7):1275-1284. PubMed ID: 28709846 [TBL] [Abstract][Full Text] [Related]
55. Biocatalytic methods for the synthesis of enantioenriched odor active compounds. Brenna E; Fuganti C; Gatti FG; Serra S Chem Rev; 2011 Jul; 111(7):4036-72. PubMed ID: 21598986 [No Abstract] [Full Text] [Related]
56. Key building blocks via enzyme-mediated synthesis. Fischer T; Pietruszka J Top Curr Chem; 2010; 297():1-43. PubMed ID: 21495255 [TBL] [Abstract][Full Text] [Related]
57. Thermophilic archaeal enzymes and applications in biocatalysis. Littlechild JA Biochem Soc Trans; 2011 Jan; 39(1):155-8. PubMed ID: 21265764 [TBL] [Abstract][Full Text] [Related]